# DeepSeek V4.1 Flash / mol-d01

Original final answer, shared by both scoring rounds.

## Bottom line

The decisive experiment is a **K-null rescue**: compare expression-matched K-WT, the available kinase-dead K (K-KD), and ideally a catalytically active scaffold mutant (K-SD) in isogenic K-null cancer cells, then measure ligand-induced phospho-S and ligand-dependent growth. The interpretation is only as good as K-KD validation. If a validated K-KD—catalytically dead, folded, expressed at WT-like levels, correctly localized, and able to bind the relevant scaffold partners—rescues both phospho-S and growth, then **K catalytic activity is not required** and a non-catalytic/scaffolding function is sufficient. If that validated K-KD fails to rescue while K-WT does, then **K catalytic activity is required** and scaffolding alone is insufficient. An invalid or unvalidated K-KD makes the experiment uninterpretable.

The fixed evidence supports the need for this design but cannot answer the question alone: M1 shows K knockout lowers ligand-stimulated phospho-S and slows growth, but a knockout removes catalytic and scaffolding functions together. M2 shows total S is unchanged, so phospho-S changes are not explained by S abundance. M3 provides only one unvalidated kinase-dead construct, so abundance, folding, localization, and scaffold integrity must be measured before any rescue result is used.

## Evidence-to-inference chain

| Evidence | Inference | What it does not establish |
|---|---|---|
| M1: pooled K knockout lowers phospho-S after ligand and slows growth | K is required for ligand-induced phospho-S and growth in this setting | Whether K acts through catalytic activity, scaffolding, or both |
| M2: total S unchanged | Phospho-S changes are not due to altered total S abundance; total S can serve as a normalization control | Whether K directly phosphorylates S |
| M3: one unvalidated kinase-dead construct | A separation-of-function reagent potentially exists | Whether it is catalytically dead, folded, stable, expressed, localized, or scaffold-intact |

Therefore, the study must separate K functions by rescue with defined alleles and must validate the kinase-dead allele before interpreting its failure or success as evidence for catalytic versus scaffolding requirement.

## Study design

### Core logic

Use K-null cells as the background and introduce:

1. **Empty vector (EV)** — negative control.
2. **K-WT** — positive rescue control.
3. **K-KD** — catalytic-dead candidate; must be validated.
4. **K-SD** — catalytically active but scaffold-deficient mutant, if it can be generated. This is not in the fixed packet but is the cleanest way to test scaffold necessity.
5. Optional: a second independent K-KD allele, or an analog-sensitive K allele plus inhibitor, to reduce single-construct artifacts.

Primary discriminating outcome:

- **K-KD rescues ligand-induced phospho-S and growth** → catalytic activity is not required; non-catalytic/scaffolding function is sufficient.
- **Validated K-KD fails to rescue, while K-WT rescues** → catalytic activity is required; the tested scaffold function alone is insufficient.
- **Partial rescue** → indeterminate; troubleshoot expression, ligand dose, clonal effects, or allele validity.

Adding K-SD sharpens the scaffold interpretation:

| Validated K-KD rescue | K-SD rescue | Interpretation |
|---|---|---|
| Full | Fails | Scaffolding sufficient; catalytic activity dispensable |
| None | Rescues | Catalytic activity sufficient; tested scaffold domain dispensable |
| None | Fails | Catalytic activity required; scaffolding alone insufficient; both may be required |
| Full | Rescues | Neither tested function is sufficient/necessary alone; redundancy or assay insensitivity |

If only K-KD is available, the main conclusion still depends on K-KD passing scaffold-intact validation.

## Operational ordered protocol

### 1. Preparation and quality checks

**Cell line preparation**

- Use the cancer cell line in which M1 was observed.
- If only a pooled K knockout exists, isolate ≥2 independent K-null clones by single-cell cloning or validate the pool with multiple independent guides.
- Validate K-null status by genomic sequencing of the edited locus, K mRNA measurement, and K protein immunoblot. Confirm absence of full-length K.
- Confirm the K-null phenotype: ligand-stimulated phospho-S is lower than parental, and growth is slower than parental, consistent with M1.
- Keep parental isogenic cells as ligand-responsive reference.

**Construct preparation and validation**

For each rescue construct:

- Sequence-verify the catalytic mutation and the entire K open reading frame.
- Use the same tag, promoter, and vector backbone across K-WT, K-KD, and K-SD. Prefer untagged or endogenous knock-in to avoid tag artifacts.
- Measure K mRNA and protein abundance.
- Calibrate expression to K-WT or endogenous K. Target K-KD abundance within approximately 0.7–1.3× K-WT after normalization to total protein and loading control. If using a wider window, predefine it, e.g., 0.5–2.0×, but do not interpret extreme overexpression as physiological rescue.
- If expression differs, titrate viral titer, use an inducible promoter, or introduce a single copy at a safe locus. For the strongest design, knock the KD allele into the endogenous K locus.

**Catalytic-dead validation**

- Run an in vitro kinase assay with immunopurified or recombinant K-WT and K-KD.
- If S is available, use S immunoprecipitate or a substrate fragment as substrate. If not, use a validated generic substrate, autophosphorylation, or ATP-consumption assay, but state that this is a surrogate.
- Acceptance: K-KD activity ≤10% of K-WT in the same assay, with K-WT activity above assay background.
- If no in vitro activity readout is available, use cell-based phospho-S as a secondary check only, not as sole validation.

**Folding and stability validation**

- Measure detergent solubility: soluble versus insoluble fraction.
- Use size-exclusion chromatography or native PAGE to check for aggregation and correct complex size.
- Use limited proteolysis or thermal shift if purified protein is available.
- Use cycloheximide chase to compare K-KD and K-WT half-life.
- Acceptance: K-KD soluble fraction ≥80% of K-WT; no major high-molecular-weight aggregate; half-life not drastically shorter, e.g., within 2-fold of K-WT unless justified.

**Scaffold-intact validation**

- Test co-immunoprecipitation of K with S and, if known, other complex members. If partners are unknown, use proximity labeling or unbiased co-IP followed by mass spectrometry to compare K-WT and K-KD interactomes.
- Test subcellular localization by immunofluorescence or fractionation.
- Acceptance: K-KD binds the key partner(s) at ≥70% of K-WT and shows the same localization pattern. If no partner is known, at minimum show K-S co-IP and correct localization.
- If K-KD fails any scaffold check, it cannot be used to conclude that catalytic activity is required.

**Ligand and assay calibration**

- In parental cells, perform a ligand dose-response: 0, and a log-spaced range around the expected active dose. Fit a four-parameter curve; choose EC50 or a saturating dose that gives a reproducible phospho-S increase.
- Perform a time course: 0, 5, 15, 30, 60, 120 min, or wider. Choose the time of maximal phospho-S for primary signaling assays.
- Confirm total S unchanged under these conditions, consistent with M2.
- For growth, calibrate doubling time and ligand-dependent growth window over 3–7 days.
- Determine assay linear range for phospho-S and growth readouts. Use only signals within the linear range.
- If equivalence margins are unknown, run a pilot with n=3 independent replicates and calculate the standard deviation of the K-WT rescue effect. Predefine the equivalence margin as the smallest biologically meaningful effect, e.g., 0.5 SD or 20% of the K-WT effect.

### 2. Independent units

- **Biological replicate**: an independent K-null clone, an independent transduction, or an independent passage. Do not treat multiple wells from the same culture as independent biological replicates.
- For signaling: use ≥3 independent K-null clones or ≥3 independent transductions per allele, each with 2–3 technical wells.
- For growth: use ≥3 independent cultures per allele, each with 3–4 technical wells.
- If using multiple clones, include clone as a random effect in the analysis.
- For the KD validation assays, use ≥3 independent protein preparations or lysates.

### 3. Allocation and blinding

- Randomize genotype and ligand/no-ligand conditions across plate positions using a random number generator.
- Balance edge wells and plate effects.
- Label samples with coded identifiers; keep the genotype key with a second person or sealed file until analysis.
- Use automated image acquisition and analysis where possible.
- For manual scoring, use two blinded scorers and predefine scoring criteria.
- Predefine primary endpoints, exclusion criteria, and analysis plan before unblinding.

### 4. Intervention and sampling

1. Seed K-null cells and parental cells at matched density.
2. Transduce or transfect with EV, K-WT, K-KD, and, if available, K-SD.
3. Select or induce, then confirm expression and KD validation checks.
4. Serum-starve cells for the calibrated period.
5. Stimulate with ligand at the calibrated dose and time.
6. For signaling: lyse at the chosen time point. Include unstimulated matched controls. Snap-freeze lysates.
7. For growth: maintain ligand continuously, replenishing at the calibrated interval. Measure at 0, 24, 48, 72, and 96 h, or until the growth window is complete.
8. Include no-ligand controls for every genotype to separate ligand-dependent from ligand-independent effects.

### 5. Measurements

**Primary signaling endpoint**

- Phospho-S normalized to total S, consistent with M2.
- Use quantitative immunoblot with fluorescent secondary antibodies, phospho-specific ELISA, or flow cytometry if validated.
- Primary metric: ligand-stimulated phospho-S fold change over unstimulated, or stimulated phospho-S normalized to total S.
- Include K protein blot to confirm expression and total S blot as loading control.

**Primary growth endpoint**

- Ligand-dependent growth: viable cell count, confluence, EdU incorporation, or colony formation.
- Primary metric: growth with ligand minus growth without ligand, or ratio of ligand-treated to vehicle-treated.
- Measure viability and apoptosis to distinguish growth arrest from cell death.

**Secondary and mechanistic endpoints**

- In vitro K catalytic activity.
- K-S co-immunoprecipitation and, if possible, other partner binding.
- K localization by immunofluorescence or fractionation.
- Downstream signaling nodes if known, but do not substitute them for phospho-S.
- Direct kinase assay: incubate K-WT or K-KD with S immunoprecipitate or substrate and measure phospho-S. This tests directness; M1 alone does not.

### 6. Controls

- Parental K-intact cells with and without ligand.
- K-null + EV with and without ligand.
- K-null + K-WT with and without ligand.
- K-null + K-KD with and without ligand.
- K-null + K-SD with and without ligand, if available.
- Tag-only or catalytically inactive unrelated kinase control to control for expression of a dead kinase.
- Pharmacological K inhibitor in K-intact cells, if a validated inhibitor exists. This supports catalytic dependence but does not distinguish scaffold effects because inhibitors can have off-target effects.
- Positive control for ligand response: parental cells must show ligand-induced phospho-S and growth.
- Negative control for rescue: EV must fail to rescue.

### 7. Analysis

- Use linear mixed-effects models: outcome ~ genotype × ligand (× time), with random effects for clone, transduction, and experiment.
- For growth, use repeated-measures or area-under-curve analysis.
- Log-transform non-normal data.
- Predefine primary comparisons:
  - K-WT versus EV: must rescue.
  - K-KD versus EV: tests whether KD rescues.
  - K-KD versus K-WT: tests equivalence or difference.
- Calculate rescue index:
  - Rescue index = (K-KD effect − EV effect) / (K-WT effect − EV effect).
  - Predefine: full rescue ≥0.7; no rescue ≤0.2; partial 0.2–0.7. Adjust thresholds after calibration if justified.
- Use equivalence testing for K-KD versus K-WT with a pre-specified margin. If the confidence interval for the difference falls within the margin and K-KD is above EV, conclude scaffolding sufficient. If K-KD is significantly below K-WT and not above EV, conclude catalytic activity required.
- Correct for multiple comparisons across primary endpoints using Holm-Bonferroni or a hierarchical testing plan.
- Report effect sizes with confidence intervals, not only p-values.

### 8. Acceptance and stopping criteria

**Assay acceptance**

- Parental cells show ligand-induced phospho-S and ligand-dependent growth above assay background.
- K-WT rescues phospho-S and growth to ≥70% of parental, or the pre-specified rescue threshold.
- EV fails to rescue.
- Total S is unchanged, consistent with M2.

**K-KD acceptance**

- Catalytic activity ≤10% of K-WT.
- Protein abundance 0.7–1.3× K-WT, or pre-specified matching window.
- Soluble, non-aggregated, stable within 2-fold of K-WT.
- Binds key partner(s) at ≥70% of K-WT and localizes correctly.

**Stopping rules**

- Stop and redesign if K-KD fails validation.
- Stop if K-WT fails to rescue; the system is not permissive.
- Stop if ligand response is absent in parental cells.
- If K-KD gives partial rescue, do not conclude; troubleshoot expression, ligand dose, clonal variation, or use a second allele.
- If the growth effect is below the calibrated minimal effect size, increase n or improve assay sensitivity.

### 9. Troubleshooting

| Problem | Action |
|---|---|
| K-KD low expression | Use endogenous knock-in, codon optimization, different promoter, or titrate titer; re-check abundance |
| K-KD insoluble/aggregated | Generate a second independent KD mutation; test different tag; use lower expression; validate by SEC and solubility |
| K-KD fails scaffold binding | Do not interpret as catalytic requirement; it is a separation-of-function failure |
| K-WT does not rescue | Check K-null clone, expression, ligand activity, and rescue construct |
| High clone-to-clone variability | Use more independent clones; include clone as random effect; use isogenic pools |
| Ligand-independent growth dominates | Normalize to no-ligand controls; increase starvation; measure ligand-dependent growth specifically |
| Signaling rescued but growth not | K may have catalytic signaling role insufficient for growth; test downstream growth pathways |
| Growth rescued but phospho-S not | K may have non-catalytic growth role; verify phospho-S assay and ligand dose |
| Only pooled knockout available | Clone and validate independent K-null lines; confirm with rescue |
| No known scaffold partner | Use co-IP with S, localization, and unbiased proximity proteomics; state scaffold validation limits |

## Discriminating outcomes and interpretation

**Outcome A: Validated K-KD fully rescues phospho-S and growth.**

- Conclusion: K catalytic activity is not required for ligand-induced signaling or growth in this cell line.
- Scaffolding or another non-catalytic function is sufficient, provided K-KD binds the relevant partners and localizes correctly.
- If K-SD fails to rescue, this strengthens the conclusion that scaffolding is required.

**Outcome B: Validated K-KD fails to rescue, while K-WT rescues.**

- Conclusion: K catalytic activity is required for ligand-induced phospho-S and growth.
- Scaffolding alone is insufficient. If K-SD rescues, catalytic activity is sufficient for the tested endpoints; if K-SD also fails, both catalytic and scaffold functions may be required.
- This does not prove K directly phosphorylates S. Directness requires in vitro kinase assay.

**Outcome C: K-KD partially rescues.**

- Conclusion: indeterminate. Possible explanations: partial loss of catalytic activity, altered scaffold function, expression mismatch, clonal adaptation, or mixed cell responses.
- Action: validate a second KD allele, improve expression matching, test more ligand doses/time points, and consider K-SD.

**Outcome D: K-KD fails validation.**

- Conclusion: no inference about catalytic versus scaffolding requirement.
- Action: generate a new allele, use endogenous knock-in, or switch to an analog-sensitive allele plus inhibitor.

## Limits and assumptions

- **K-KD validity is the main limit.** A kinase-dead mutation can misfold, degrade, mislocalize, or lose partner binding. The study must measure these; otherwise a failure to rescue could be a construct artifact.
- **Scaffolding is not a single property.** K-KD may preserve some interactions but not others. If the relevant scaffold partner is unknown, scaffold-intact validation is incomplete.
- **Rescue may not recapitulate endogenous regulation.** Overexpression can create artificial scaffolding. Endogenous knock-in or single-copy expression is preferred.
- **M1 used a pooled knockout.** Pooled populations can have heterogeneity or adaptation. Independent clonal K-null lines and rescue are needed.
- **M1/M2 do not prove direct K-to-S phosphorylation.** They show requirement. Direct kinase activity requires in vitro or rapid kinetic assays.
- **Growth is indirect.** Slowed growth could reflect cell cycle arrest, death, paracrine effects, or altered metabolism. Viability and apoptosis controls help distinguish these.
- **Ligand dose, time, K partners, S identity, and growth assay conditions are not specified in the packet.** These must be calibrated in the user’s system rather than assumed.
- **Equivalence margins are study-specific.** They should be pre-registered after pilot calibration. Without them, “full rescue” versus “no rescue” can become arbitrary.
- **The question asks “catalytic activity rather than scaffolding.”** If both functions are required, the binary framing fails. The K-KD plus K-SD matrix is needed to detect that possibility.
- **Cell-line specificity.** Conclusions apply to the tested cancer line under the tested ligand and growth conditions. They should not be generalized without validation in other lines or models.
